PDS Biotechnology (PDSB) Competitors $1.63 +0.11 (+7.24%) As of 12:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends PDSB vs. CADL, MOLN, FULC, LRMR, FDMT, ACB, OCGN, SOPH, HURA, and CGENShould you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Candel Therapeutics (CADL), Molecular Partners (MOLN), Fulcrum Therapeutics (FULC), Larimar Therapeutics (LRMR), 4D Molecular Therapeutics (FDMT), Aurora Cannabis (ACB), Ocugen (OCGN), SOPHiA GENETICS (SOPH), TuHURA Biosciences (HURA), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. PDS Biotechnology vs. Candel Therapeutics Molecular Partners Fulcrum Therapeutics Larimar Therapeutics 4D Molecular Therapeutics Aurora Cannabis Ocugen SOPHiA GENETICS TuHURA Biosciences Compugen Candel Therapeutics (NASDAQ:CADL) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment. Does the MarketBeat Community favor CADL or PDSB? PDS Biotechnology received 61 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 69.61% of users gave PDS Biotechnology an outperform vote while only 55.56% of users gave Candel Therapeutics an outperform vote. CompanyUnderperformOutperformCandel TherapeuticsOutperform Votes1055.56% Underperform Votes844.44% PDS BiotechnologyOutperform Votes7169.61% Underperform Votes3130.39% Which has more volatility and risk, CADL or PDSB? Candel Therapeutics has a beta of -1.2, indicating that its stock price is 220% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Which has higher valuation and earnings, CADL or PDSB? Candel Therapeutics has higher revenue and earnings than PDS Biotechnology. Candel Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K1,893.58-$37.94M-$1.73-4.04PDS BiotechnologyN/AN/A-$42.94M-$1.16-1.41 Is CADL or PDSB more profitable? PDS Biotechnology's return on equity of -139.57% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -629.29% -173.39% PDS Biotechnology N/A -139.57%-67.22% Do analysts prefer CADL or PDSB? Candel Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 171.58%. PDS Biotechnology has a consensus price target of $11.67, indicating a potential upside of 615.75%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Candel Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer CADL or PDSB? In the previous week, Candel Therapeutics and Candel Therapeutics both had 1 articles in the media. Candel Therapeutics' average media sentiment score of 1.87 equaled PDS Biotechnology'saverage media sentiment score. Company Overall Sentiment Candel Therapeutics Very Positive PDS Biotechnology Very Positive Do institutionals and insiders hold more shares of CADL or PDSB? 13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 41.6% of Candel Therapeutics shares are owned by company insiders. Comparatively, 9.5% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryPDS Biotechnology beats Candel Therapeutics on 12 of the 15 factors compared between the two stocks. Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PDSB vs. The Competition Export to ExcelMetricPDS BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.60M$6.83B$5.58B$9.11BDividend YieldN/A2.96%5.36%3.98%P/E Ratio-1.409.7388.4717.54Price / SalesN/A346.631,263.0482.41Price / CashN/A65.0944.3037.67Price / Book1.945.265.104.72Net Income-$42.94M$154.67M$117.69M$224.52M7 Day Performance7.95%0.55%0.92%-0.56%1 Month Performance-3.55%1.18%10.21%4.62%1 Year Performance-70.79%7.08%26.31%18.89% PDS Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PDSBPDS Biotechnology1.6695 of 5 stars$1.63+7.2%$11.67+615.7%-74.2%$60.60MN/A-1.4020Positive NewsCADLCandel Therapeutics3.5704 of 5 stars$6.66-13.4%$19.00+185.3%+439.8%$216.32M$120,000.00-3.8560Positive NewsGap UpMOLNMolecular Partners0.3864 of 5 stars$5.36-7.8%N/A+10.2%$216.13M$7.84M-2.49180Gap DownFULCFulcrum Therapeutics1.9918 of 5 stars$3.96-0.5%$9.33+135.7%-45.5%$213.60M$2.81M-12.77100News CoveragePositive NewsLRMRLarimar Therapeutics1.724 of 5 stars$3.34+2.8%$20.43+511.6%-27.3%$213.13MN/A-2.9030Analyst ForecastNews CoverageFDMT4D Molecular Therapeutics3.5117 of 5 stars$4.58-2.1%$38.56+741.8%-72.3%$211.73M$20.72M-1.61120Short Interest ↓ACBAurora Cannabis0.2466 of 5 stars$3.85-2.8%N/A-9.5%$211.29M$200.35M-5.071,073Upcoming EarningsShort Interest ↑OCGNOcugen2.2945 of 5 stars$0.71-0.7%$5.67+698.1%+30.6%$206.84M$6.04M-3.9480SOPHSOPHiA GENETICS2.8782 of 5 stars$3.12+4.7%$7.40+137.2%-18.6%$203.99M$62.37M-2.86520Short Interest ↓Gap DownHURATuHURA BiosciencesN/A$4.79+1.3%$13.00+171.4%N/A$202.55MN/A0.00N/ANews CoveragePositive NewsGap UpCGENCompugen2.5648 of 5 stars$2.25+6.1%$4.00+77.8%-4.1%$200.79M$33.46M112.5070News CoveragePositive NewsHigh Trading Volume Related Companies and Tools Related Companies CADL Competitors MOLN Competitors FULC Competitors LRMR Competitors FDMT Competitors ACB Competitors OCGN Competitors SOPH Competitors HURA Competitors CGEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PDSB) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
